PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced consolidated 2011 financial results, reviewed key 2011 accomplishments and reiterated that it expects to initiate the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension) in the U.S. the week of April 9. EXPAREL was approved by the U.S. Food and Drug Administration in October 2011, and Pacira deployed a field force of 63 hospital specialists into the marketplace in January 2012.
